Healthcare Industry News:  mixed amphetamine salts 

Biopharmaceuticals Acquisitions

 News Release - September 28, 2006

Barr Cleared to Launch ADDERALL(R) IR

Hart-Scott-Rodino Waiting Period Expires Without Comment from Federal Trade Commission

WOODCLIFF LAKE, N.J., Sept. 28 (HSMN NewsFeed) -- Barr Pharmaceuticals, Inc. (NYSE: BRL ) today announced that the Hart-Scott-Rodino ("HSR") waiting period for the Company's acquisition of Shire plc's ADDERALLŽ (immediate-release mixed amphetamine salts) product has expired without further action from the U.S. Federal Trade Commission ("FTC"). As a result, the product acquisition agreement that Duramed Pharmaceuticals, Inc., a subsidiary of Barr, and Shire entered into on August 14, 2006 can be finalized. Under the terms of the agreement, Duramed will pay $63 million to purchase Shire's ADDERALL (immediate-release mixed amphetamine salts) tablets. The Company will launch the ADDERALL product in the quarter ending December 31, 2006.

On August 14, 2006, the Company announced that it and Shire had signed an agreement that provided for Duramed to purchase ADDERALL (immediate-release mixed amphetamine salts) tablets. On August 28, 2006, Barr and Shire filed the agreement with the FTC pursuant to the Hart-Scott-Rodino Antitrust Improvements Act. On September 27, 2006, the initial 30-day HSR waiting period expired without further FTC action. The parties are therefore free to close.

ADDERALL is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability and impulsivity.

About Barr

Barr Pharmaceuticals, Inc. is a holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceuticals. For more information about Barr, please visit Barr's website at http://www.barrlabs.com.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; changes in generally accepted accounting principles; and other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended June 30, 2005.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.


Source: Barr Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.